This article hit the nail on the head with where i see biotech moving in the coming years. Specifically, the fact that physical/biological data is commoditized is inevitable. We've seen it happen with 23&Me and others. Everything is going to be indexed and queryable. Access to that data for modeling and interpretation will mint fortune for the companies that do it right. This is why stuff like ABCL, ABSI are going to massively rerate on both narrative and if they can prove their models.(CryptoCondom)